Last $112.26 USD
Change Today +0.48 / 0.43%
Volume 3.3M
MDVN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
As of 8:10 PM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

medivation inc (MDVN) Snapshot

Open
$111.42
Previous Close
$111.78
Day High
$112.33
Day Low
$109.00
52 Week High
11/7/14 - $113.61
52 Week Low
04/14/14 - $54.37
Market Cap
8.7B
Average Volume 10 Days
1.1M
EPS TTM
$1.41
Shares Outstanding
77.6M
EX-Date
07/27/99
P/E TM
79.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIVATION INC (MDVN)

medivation inc (MDVN) Related Businessweek News

View More BusinessWeek News

medivation inc (MDVN) Details

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company also conducts various trials of enzalutamide in earlier prostate cancer disease states, including the Phase III PREVAIL trial in patients with mCRPC who have not received chemotherapy; and in patients with breast cancer. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI. The company is headquartered in San Francisco, California.

468 Employees
Last Reported Date: 11/6/14

medivation inc (MDVN) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $750.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $480.4K
General Counsel and Corporate Secretary
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2013.

medivation inc (MDVN) Key Developments

Medivation, Inc. Announces Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revised Earnings Guidance for the Full Year of 2014

Medivation, Inc. announced consolidated unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported collaboration revenues of $200,478,000 compared with $60,027,000 for the same period a year ago. Income from operations was $91,883,000 compared with loss from operations of $7,998,000 for the same period a year ago. Income before income tax expense was $86,412,000 compared with loss before income tax expense of $13,255,000 for the same period a year ago. Net income was $77,993,000 or $0.96 per diluted share compared with net loss of $13,313,000 or $0.18 per diluted share for the same period a year ago. For the nine months, the company reported collaboration revenues of $435,757,000 compared with $176,330,000 for the same period a year ago. Income from operations was $138,369,000 compared with loss from operations of $30,266,000 for the same period a year ago. Income before income tax expense was $122,218,000 compared with loss before income tax expense of $45,258,000 for the same period a year ago. Net income was $112,247,000 or $1.39 per diluted share compared with net loss of $45,381,000 or $0.60 per diluted share for the same period a year ago. The company revised earnings guidance for the full year of 2014. U.S. net sales of XTANDI, as reported by Astellas, are expected to be at the high end or just above the previously-guided range between $600 million and $640 million. Total collaboration revenue is expected to be at the high end or just above the previously-guided range between $615 million and $640 million, which includes collaboration revenue related to U.S. net sales of XTANDI that is expected to be at the high end or just above the previously-guided range between $300 million and $320 million, and collaboration revenue related to upfront and milestone payments of approximately $279 million. Total operating expenses, net of cost-sharing payments from Astellas, are expected to be in the lower half of the previously-guided range between $400 million and $430 million, approximately $45 million to $50 million of which consists of non-cash stock-based compensation expense. SG&A expenses are expected to represent just over half of full year operating expenses. Effective tax rate is expected to approximate 36% or 37% for the subsequent periods.

Medivation, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 08:00 AM

Medivation, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 08:00 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom. Speakers: David T. Hung, Founder, Chief Executive Officer, President and Executive Director, Rick Bierly, Chief Financial Officer and Principal Accounting Officer.

Medivation Inc. and Astellas Announces Plans to Initiate Global Phase 3 Clinical Trial

Medivation Inc. and Astellas announced plans to initiate a global Phase 3 clinical trial that will evaluate the efficacy and safety of enzalutamide in patients with high-risk, hormone-sensitive, non-metastatic prostate cancer that has biochemically recurred (rising prostate-specific antigen [PSA] level) following definitive local therapy with radical prostatectomy and/or radiation therapy. Currently there is no prescription medicine specifically approved in the United States for these patients. The Phase 3 randomized, multi-national trial will be conducted at approximately 160 sites and is designed to enroll approximately 1,860 hormone-sensitive, non-metastatic men with biochemical recurrence following prostatectomy and/or radiation therapy that are at high risk for morbidity and mortality from prostate cancer. The trial will evaluate enzalutamide at a dose of 160 mg to be taken orally once daily. Leuprolide acetate will be given as an injection of 22.5 mg once every 12 weeks for a minimum of 3 doses. All patients will be treated for 37 weeks.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDVN:US $112.26 USD +0.48

MDVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $7.11 USD -0.04
Insys Therapeutics Inc $38.90 USD -0.02
Pfizer Ltd/India 1,790 INR +89.20
Sanofi India Ltd 3,680 INR +4.05
Seattle Genetics Inc $36.65 USD -0.70
View Industry Companies
 

Industry Analysis

MDVN

Industry Average

Valuation MDVN Industry Range
Price/Earnings 77.2x
Price/Sales 16.2x
Price/Book 34.8x
Price/Cash Flow 75.4x
TEV/Sales 15.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVATION INC, please visit www.medivation.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.